ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.16, Zacks reports.
ENDRA Life Sciences Stock Performance
NDRA traded up $0.02 during trading on Monday, hitting $4.43. The stock had a trading volume of 4,492 shares, compared to its average volume of 51,423. The firm has a market capitalization of $6.64 million, a P/E ratio of -0.69 and a beta of -0.07. ENDRA Life Sciences has a twelve month low of $2.96 and a twelve month high of $6.95. The company’s 50-day moving average price is $5.35 and its 200 day moving average price is $4.82.
Analyst Ratings Changes
Separately, Weiss Ratings cut shares of ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.00.
Check Out Our Latest Stock Report on ENDRA Life Sciences
About ENDRA Life Sciences
ENDRA Life Sciences is a medical technology company developing imaging tools for the assessment of liver disease. Its technology is designed to provide clinicians with a non-invasive way to evaluate liver tissue and support the monitoring of conditions such as fatty liver disease. The company’s lead platform, TAEUS (Thermo-Acoustic Enhanced Ultrasound), combines radiofrequency energy with ultrasound to measure tissue characteristics, including liver fat. ENDRA is developing the system as an alternative or complement to existing approaches to liver assessment.
Read More
- Five stocks we like better than ENDRA Life Sciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
